IACH Post-EBMT 2026 Roundtable Discussion to summarize and reflect on the key highlights of the meeting – Tuesday, March 31, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content IACH Post-EBMT 2026 Roundtable Discussion to summarize and reflect on the key highlights of the meeting – Tuesday, March 31, 2026 Read More »
Role of supplemental nutritional therapies in cancer patients – Thursday, March 26, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content Role of supplemental nutritional therapies in cancer patients – Thursday, March 26, 2026 Read More »
Multiple Myeloma Academy – Journal Club – Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial – Tuesday, March 10, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Academy – Journal Club – Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial – Tuesday, March 10, 2026 Read More »
Supportive care in chronic GVHD – Monday, March 9, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content Supportive care in chronic GVHD – Monday, March 9, 2026 Read More »
CLL Academy – Management of CLL in real life – Thursday, February 26, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content CLL Academy – Management of CLL in real life – Thursday, February 26, 2026 Read More »
Multiple Myeloma Academy – Journal Club – Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study – Monday, February 23, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Academy – Journal Club – Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study – Monday, February 23, 2026 Read More »
New medicine approved to treat Chronic Graft-Versus-Host Disease – Wednesday, February 18, 2026 Uncategorized / Sharon Rawet Lederer Open to access this content New medicine approved to treat Chronic Graft-Versus-Host Disease – Wednesday, February 18, 2026 Read More »
IACH Annual Meeting 2026 Scientific Program course – October 15-17, 2026 – Live Broadcast CME credits / Sharon Rawet Lederer Open to access this content IACH Annual Meeting 2026 Scientific Program course – October 15-17, 2026 – Live Broadcast Read More »
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma – Monday, June 16, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma – Monday, June 16, 2025 Read More »
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis – Tuesday, October 14, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis – Tuesday, October 14, 2025 Read More »
